Profile data is unavailable for this security.
About the company
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.
- Revenue in USD (TTM)65.00k
- Net income in USD-279.42m
- Incorporated2017
- Employees232.00
- LocationAllogene Therapeutics Inc210 East Grand AvenueSOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 457-2700
- Fax+1 (302) 636-5454
- Websitehttps://allogene.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Foghorn Therapeutics Inc. | 35.19m | -86.45m | 552.73m | 116.00 | -- | -- | -- | 15.71 | -1.95 | -1.95 | 0.7895 | -0.2589 | 0.1053 | -- | -- | 303,319.00 | -25.88 | -31.35 | -30.84 | -35.69 | -- | -- | -245.69 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
Altimmune Inc | 409.00k | -101.35m | 553.64m | 59.00 | -- | 3.63 | -- | 1,353.65 | -1.62 | -1.62 | 0.0064 | 2.15 | 0.0023 | -- | 1.46 | 6,932.20 | -56.83 | -39.62 | -61.41 | -42.58 | -- | -- | -24,778.97 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
Arcturus Therapeutics Holdings Inc | 163.87m | -71.96m | 557.34m | 180.00 | -- | 2.16 | -- | 3.40 | -2.68 | -2.68 | 6.11 | 9.56 | 0.40 | -- | 12.19 | 910,366.70 | -17.57 | -19.66 | -22.59 | -24.90 | -- | -- | -43.92 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
Alector Inc | 55.28m | -160.66m | 559.60m | 245.00 | -- | 3.72 | -- | 10.12 | -1.81 | -1.81 | 0.6162 | 1.55 | 0.0864 | -- | -- | 226,536.90 | -25.11 | -20.00 | -32.15 | -23.81 | -- | -- | -290.66 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
Eliem Therapeutics Inc | 0.00 | -64.20m | 565.32m | 9.00 | -- | 2.53 | -- | -- | -2.15 | -2.15 | 0.00 | 3.33 | 0.00 | -- | -- | 0.00 | -37.51 | -- | -38.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
Regenxbio Inc | 89.04m | -241.08m | 577.76m | 344.00 | -- | 1.66 | -- | 6.49 | -5.27 | -5.27 | 1.93 | 7.06 | 0.1423 | -- | 4.03 | 258,848.80 | -38.52 | -16.75 | -46.55 | -19.08 | 56.78 | 78.27 | -270.74 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
SS Innovations International Inc | 14.41m | -23.68m | 580.51m | 239.00 | -- | 34.18 | -- | 40.29 | -0.1396 | -0.1396 | 0.0847 | 0.0995 | 0.6003 | 2.28 | 5.08 | 60,293.01 | -98.66 | -161.38 | -216.15 | -449.76 | 28.42 | -79.79 | -164.35 | -495.77 | 0.9128 | -45.39 | 0.4172 | -- | -- | -- | -846.31 | -- | 159.31 | -- |
Mineralys Therapeutics Inc | 0.00 | -119.67m | 582.30m | 28.00 | -- | 2.01 | -- | -- | -2.71 | -2.71 | 0.00 | 5.84 | 0.00 | -- | -- | 0.00 | -39.26 | -- | -41.62 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
Allogene Therapeutics Inc | 65.00k | -279.42m | 585.51m | 232.00 | -- | 1.14 | -- | 9,007.88 | -1.59 | -1.59 | 0.0004 | 2.46 | 0.00009 | -- | -- | 280.17 | -39.41 | -28.46 | -42.15 | -30.21 | -- | -- | -429,881.50 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
Tourmaline Bio Inc | 0.00 | -35.69m | 590.26m | 44.00 | -- | 1.75 | -- | -- | -2.54 | -2.54 | 0.00 | 13.19 | 0.00 | -- | -- | 0.00 | -14.16 | -- | -14.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
Q32 Bio Inc | 0.00 | -65.02m | 590.69m | 41.00 | -- | 17.53 | -- | -- | -16.24 | -16.24 | 0.00 | 2.79 | 0.00 | -- | -- | 0.00 | -31.38 | -34.98 | -36.35 | -37.92 | -- | -- | -- | -971.76 | -- | -- | 0.2725 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
Lexicon Pharmaceuticals Inc | 3.64m | -202.11m | 600.08m | 285.00 | -- | 2.50 | -- | 164.81 | -0.7783 | -0.7783 | 0.0139 | 0.6639 | 0.0106 | 0.7239 | 2.20 | 12,775.44 | -58.57 | -24.41 | -63.55 | -29.01 | 92.47 | 98.49 | -5,550.87 | -84.92 | 11.49 | -11.96 | 0.2931 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
Y-mAbs Therapeutics Inc | 86.55m | -24.61m | 611.94m | 100.00 | -- | 6.42 | -- | 7.07 | -0.5618 | -0.5618 | 1.98 | 2.14 | 0.6262 | 1.42 | 4.19 | 865,460.00 | -17.81 | -44.23 | -23.58 | -50.45 | 88.74 | -- | -28.44 | -181.13 | 2.72 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
Lenz Therapeutics Inc | 0.00 | -72.31m | 615.65m | 6.00 | -- | 3.00 | -- | -- | -9.45 | -9.45 | 0.00 | 7.46 | 0.00 | -- | -- | 0.00 | -29.53 | -- | -30.84 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.35 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 25.36m | 12.15% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 9.18m | 4.40% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 8.11m | 3.89% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 8.04m | 3.85% |
PRIMECAP Management Co.as of 30 Jun 2024 | 5.67m | 2.72% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 4.12m | 1.97% |
JPMorgan Investment Management, Inc.as of 31 Mar 2024 | 3.61m | 1.73% |
Citadel Advisors LLCas of 31 Mar 2024 | 3.11m | 1.49% |
Geode Capital Management LLCas of 30 Jun 2024 | 2.82m | 1.35% |
Woodline Partners LPas of 31 Mar 2024 | 2.63m | 1.26% |